85 related articles for article (PubMed ID: 9918196)
1. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention.
Muggia FM
Clin Cancer Res; 1999 Jan; 5(1):7-8. PubMed ID: 9918196
[No Abstract] [Full Text] [Related]
2. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
5. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
6. Polymer-protein and polymer-drug conjugates in cancer therapy.
Thanou M; Duncan R
Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
[TBL] [Abstract][Full Text] [Related]
8. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
9. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
10. Polymer conjugates: nanosized medicines for treating cancer.
Vicent MJ; Duncan R
Trends Biotechnol; 2006 Jan; 24(1):39-47. PubMed ID: 16307811
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
12. Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene-platinum (II) conjugates.
Jun YJ; Kim JI; Jun MJ; Sohn YS
J Inorg Biochem; 2005 Aug; 99(8):1593-601. PubMed ID: 15963570
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug.
Ahmed F; Pakunlu RI; Brannan A; Bates F; Minko T; Discher DE
J Control Release; 2006 Nov; 116(2):150-8. PubMed ID: 16942814
[TBL] [Abstract][Full Text] [Related]
14. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
15. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
16. Eudragit FS 30 D: a new pH-sensitive polymer covering for mesalamine.
Potestà P
Eur Rev Med Pharmacol Sci; 2001; 5(1):30. PubMed ID: 11860220
[No Abstract] [Full Text] [Related]
17. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
Duncan R; Vicent MJ; Greco F; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S189-99. PubMed ID: 16113096
[TBL] [Abstract][Full Text] [Related]
18. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
19. New possibilities of application of multifunctional polymers and polymer conjugates.
Pluta J; Karolewicz B
Acta Pol Pharm; 2003; 60(3):211-4. PubMed ID: 14556491
[TBL] [Abstract][Full Text] [Related]
20. Cellular evaluation of oral chemotherapy carriers.
Blanchette J; Peppas NA
J Biomed Mater Res A; 2005 Mar; 72(4):381-8. PubMed ID: 15666363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
